Description
When is ponatinib a suitable treatment option for patients with chronic phase CML and how can we optimize the benefit/risk ratio?
€3.03
When is ponatinib a suitable treatment option for patients with chronic phase CML and how can we optimize the benefit/risk ratio?
Notifications
Reviews
There are no reviews yet.